A Phase 2/3, Prospective, Randomized, Multi-center, Open-Label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-102 for Induction of Immune Quiescence™in Recipients of HLA-mismatched, Living Donor Kidney Transplants
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 22 Jan 2019
At a glance
- Drugs MDR 102 (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Medeor Therapeutics
- 11 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Mar 2019.
- 26 Jul 2018 Status changed from planning to not yet recruiting.
- 30 Nov 2017 New trial record